BI 836858

Drug Profile

BI 836858

Alternative Names: BI-836858

Latest Information Update: 14 Mar 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 09 Mar 2017 BI 836858 receives Orphan Drug status for Acute myeloid leukaemia in USA before March 2017
  • 09 Mar 2017 BI 836858 receives Orphan Drug status for Myelodysplastic syndromes in USA
  • 18 Oct 2016 The Leukemia and Lymphoma Society plans a Beat AML Master trial for Acute myeloid leukaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top